Meta Platforms earnings missed by $5.63, revenue topped estimates
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a $460 million market cap biotech company, sold 1,635 shares of common stock on October 16, 2025, for $10.17 per share, totaling $16,627. The stock has shown remarkable strength, surging over 220% in the past six months and currently trading near its 52-week high of $10.73. InvestingPro subscribers can access comprehensive insider trading analysis and 14 additional key insights about FDMT.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction was executed under a pre-arranged 10b5-1 trading plan. On the same day, Bizily exercised options to acquire 1,635 shares of 4D Molecular Therapeutics common stock at a price of $4.14, for a total value of $6,768. Analysts maintain a bullish outlook on the stock, with price targets ranging from $16 to $45.
Following the sale, Bizily directly owns 5,188 shares of 4D Molecular Therapeutics. He also holds options to purchase 76,865 shares.
In other recent news, 4D Molecular Therapeutics has continued to make headlines with its recent developments. The company reported positive 60-week results from its SPECTRA clinical trial for the 4D-150 treatment in diabetic macular edema (DME). The trial demonstrated durable and dose-dependent clinical activity, resulting in a 78% reduction in treatment burden at the Phase 3 dose level compared to standard treatments. This announcement follows the company’s second-quarter earnings report, after which Goldman Sachs reiterated its Buy rating and set a price target of $38.00. Additionally, 4D Molecular Therapeutics has initiated Phase 3 studies for its 4D-150 treatment aimed at wet age-related macular degeneration (AMD). These studies are expected to yield topline data in the first and second halves of 2027. The company’s ongoing advancements in clinical trials and subsequent regulatory updates continue to attract attention from investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.